Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.45 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427072 | 0.84 | SCN9A (0.38) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2425438 | 0.83 | SCN9A (0.46) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2431152 | 0.80 | SCN9A (0.44) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2434034 | 0.79 | ALDH1A1 (0.39) | SCN9AALDH1A1GAACES1 | |
| SCHEMBL3343014 | 0.73 | SCN9A (0.51) | SCN9AALDH1A1GAACES1USP2 | |
| SCHEMBL3349347 | 0.72 | ALDH1A1 (0.38) | ALDH1A1GAACES1USP2 | |
| SCHEMBL281951 | 0.69 | SCN9A (0.70) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2426206 | 0.69 | SCN9A (0.45) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Hydrochloric Acid SCHEMBL281534 | 0.69 | SCN9A (0.68) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL281665 | 0.68 | SCN9A (0.73) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| WO-2008046046-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160291-A1 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, SCN3A, CACNA1A | SCN9A 57/4885SCN7A 54/4885SCN5A 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.